Esomeprazole 20mg Provides More Effective Intragastric Acid Control than Maintenance-Dose Rabeprazole, Lansoprazole or Pantoprazole in Healthy Volunteers

Clinical Drug Investigation

Volumn 24, Issue 1, 2004, Pages 1-7

  Röhss, Kerstin ^a   Wilder Smith, Clive ^b   Nauclér, Emma ^a   Jansson, Lennart ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b Gastroenterology Group Practice   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFECT; EXTERNAL OTITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAINTENANCE DRUG DOSE; MALE; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STOMACH PH; THROAT DISEASE; TREATMENT OUTCOME; VULVITIS;

EID: 1042267995     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424010-00001     Document Type: Article

References (25)

1. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159 (7): 649-57
2. Olbe L, Lundell L. Medical treatment of reflux esophagitis. Hepatogastroenterology 1992; 39 (4): 322-4
3. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340 (11): 825-31
4. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59-67
5. Havelund TT, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94 (7): 1782-9
6. Revicki DA, Wood M, Maton PN, et al. The impact of gastro-esophageal reflux disease on health-related quality of life. Am J Med 1998; 104 (3): 252-8
7. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112 (6): 1798-810
8. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14 (7): 861-7
9. Röhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole 40mg provides more effective acid control than standard doses of all other proton pump inhibitors [abstract]. Gastroenterology 2001; 120: A419
10. Miner PB, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20
11. National Institute for Clinical Excellence 2000. Guidance on the use of proton pump inhibitors (PPIs) in the treatment of dyspepsia [online]. Available from URL: http://www.nice-.org.uk [Accessed 2003 Sep 12]
12. DeVault KR, Castell DO, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-42
13. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval workshop report. Gut 1999; 44 Suppl. 2: S1-16
14. Wilder-Smith C, Röhss K, Claar-Nilsson C. Esomeprazole 20mg provides more effective acid control than lansoprazole 15mg [abstract]. Gut 2000; 47 Suppl. 3: A62
15. Röhss K, Claar-Nilsson C, Jansson L. Esomeprazole 20mg provides more effective acid control than rabeprazole 10mg following repeated drug administration. Scand J Gastroenterol 2002; 37 (6 Suppl. 235): 2-38
16. Nilsson-Pieschl C, Lundin C, Hjalmar K, et al. Esomeprazole 20mg provides faster and more effective acid control than pantoprazole 20mg in healthy volunteers. Scand J Gastroenterol 2003; 38 Suppl 238: A-P3
17. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol 1994; 29 Suppl. 201: 79-82
18. Thomson ABR, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40mg provides more effective acid control than lansoprazole 30mg during single and repeated administration [abstract]. Gut 2000; 47 Suppl. 3: 63
19. Lauritsen K, Deviere J, Bigard M-A. Esomeprazole 20mg is more effective than lansoprazole 15mg in the maintenance treatment of patients with healed reflux oesophagitis. Aliment Pharmacol Ther 2003; 17 (3): 333-41
20. Johnson DA, Vakil NB, Hwang C, et al. Impact of esomeprazole on symptom control in patients with healed erosive esophagitis [abstract 2247]. Gastroenterology 2001; 120 (5 Suppl. 1): A441
21. Blum RA, Shi H, Karol MD, et al. The comparative effects of lansoprazole, omeprazole and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19 (5): 1013-23
22. Tutuian R, Katz PO, Bochenek W, et al. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40mg, in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 829-36
23. Baisley KJ, Warrington S, Tejura B, et al. Rabeprazole 20mg compared with esomeprazole 40mg in the control of intragastric pH in healthy volunteers [abstract 148]. Am J Gastroenterol 2001; 96 (9 Suppl.): S48
24. Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20mg, or esomeprazole, 20mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-7
25. Hirschowitz BI. A critical analysis with appropriate controls of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58